Joseph Talvacchia, DO
Gynecology · Philadelphia, PANPI 1245277128
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $74,500 of the $85,121 with a category attached, or 87.5%. AbbVie accounts for 96.3% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $55,030 and has fallen 99.4% since, to $355 in 2025. Among gynecology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 268 payments — averaging $317.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$82K
- Scynexis, Inc.$1K
- Innocoll Pharmaceuticals Limited$575
- Astellas Pharma US Inc$506
- Sumitomo Pharma America, Inc.$321
- Novo Nordisk$125
- plus $491 from 14 others
What the payments were for
- Consulting fees$1,5752%
- Speaking & faculty fees$74,50088%
- Travel & lodging$4,1445%
- Food & beverage$4,6065%
- Education$2970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 214 | $81,981 |
| Scynexis, Inc. | 2 | $1,124 |
| Innocoll Pharmaceuticals Limited | 1 | $575 |
| Astellas Pharma US Inc | 14 | $506 |
| Sumitomo Pharma America, Inc. | 11 | $321 |
| Novo Nordisk | 1 | $125 |
| Mayne Pharma Commercial LLC | 5 | $88 |
| Urovant Sciences Inc | 4 | $76 |
| Coopersurgical, Inc. | 2 | $66 |
| Pfizer | 4 | $57 |
| Intuitive Surgical | 1 | $40 |
| Davol Inc. | 1 | $29 |
| Dysis Medical, Inc. | 1 | $25 |
| Therapeuticsmd, Inc. | 1 | $23 |
| Lupin Inc. | 1 | $19 |
| Myovant Sciences Inc. | 1 | $16 |
| Agile Therapeutics, Inc. | 1 | $15 |
| Avion Pharmaceuticals | 1 | $14 |
| Mission Pharmacal Company | 1 | $13 |
| Millicent US Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$85,121 in reported general payments places this provider in the 95th percentile of 98 gynecology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyfembreeRelugolix/Estradiol/Norethindr | 11 | $12,094 |
| Estradiol | 159 | $8,372 |
| Estradiol (Once Weekly)Estradiol | 36 | $3,532 |
| Metronidazole | 88 | $1,857 |
| Norethindrone Acetate | 34 | $996 |
| ValacyclovirValacyclovir Hcl | 34 | $964 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 45 | $543 |
| Oxybutynin Chloride ErOxybutynin Chloride | 25 | $527 |
| Clobetasol Propionate | 24 | $278 |
| SprintecNorgestimate-Ethinyl Estradiol | 11 | $204 |
| Fluconazole | 32 | $101 |
| Sertraline Hcl | 14 | $72 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $34 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Myfembree | $321 | $12,09411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 98 gynecology providers in Pennsylvania.
Other gynecology in Philadelphia
- Reneita RossPhiladelphia$8K
- Michael KinsonPhiladelphia$4K
- Udele TagoePhiladelphia$2K
- Eugene AndruczykPhiladelphia$2K
- Christine WuPhiladelphia$2K
- Richard KraussPhiladelphia$923
- Shwetha ShrivatsaPhiladelphia$780
- Gail SullivanPhiladelphia$628
- Maureen KellyPhiladelphia$609
- Wendy PowellPhiladelphia$553
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.